CD134 (OX40) Monoclonal Antibody (OX-86), Functional Grade, eBioscience™

Product Specific Information

Description: The OX-86 monoclonal antibody reacts with mouse CD134, also known as OX40. A member of the TNF receptor superfamily, CD134 is a 50 kDa type I membrane glycoprotein expressed by activated mouse T lymphocytes. Rat CD134 was initially identified as an activation marker only on activated CD4+ T cells. In contrast, mouse CD134 is expressed by both activated CD4+ and CD8+ T cells. The interaction of CD134 with CD252 (OX40 ligand) has been implicated in T cell-dependent humoral responses, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool, and regulation of tolerance in the CD4+ T cell compartment.

Applications Reported: The OX-86 antibody has been reported for use in flow cytometric analysis. It does not block binding of CD134 to its ligand, but has been reported for use in functional assays.

Applications Tested: The OX-86 antibody has been tested by flow cytometric analysis of activated mouse splenocytes. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

Target Information

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.